The Wilm’s Tumor (Nephroblastoma) market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Wilm’s Tumor (Nephroblastoma): An Overview
Nephroblastoma also is known as Wilms’ tumor is an embryonal type of renal cancer, is one of the most common solid malignant neoplasms in children. It accounts for approximately 90% of all pediatric tumors of the kidney. The total number of new cases of Wilms’ tumor in the UK is estimated at 80 cases per year. The tumor usually arises in a single kidney. Synchronous bilateral or multifocal tumors occur in approximately 10% of patients and tend to present at an earlier age. Wilms’ tumor can also be diagnosed in adolescents or adults, but this is extremely rare, representing less than 1% of all renal tumors.
The usual treatment approach in most patients is a combination of surgery and chemotherapy, with the addition of radiotherapy in high-risk patients. Substantial progress in the treatment of Wilms’ tumor over the past few decades has been made by refining risk stratification and by the use of existing chemotherapy schedules. This has improved overall survival (OS) for patients with Wilms’ tumor in high-income countries to greater than 90% for localized disease and 75% for metastatic disease.
Wilm’s Tumor (Nephroblastoma) Market Key Facts
-
Wilms’ tumor affects one in 10,000 children and accounts for 5% of all childhood cancers. More than 80% of children are diagnosed with Wilms’ tumor below the age of five years, and the median age at diagnosis is 3.5 years.
-
Wilms is more common in Africans and African Americans while it is least common in East Asians. Asian patients also had fewer unfavorable histology tumors, tend to have a lower-stage disease, and enjoy better survival outcomes. European and North American rates are about the same. This variation suggests that genetic factors play the most important role in its etiology.
-
Wilms tumor is the most common abdominal cancer in childhood and typically presents between ages 3 to 5 years. There are approximately 650 new cases in the United States every year. Girls are slightly more likely to have Wilms than boys. The male to female ratio in unilateral cases of Wilms tumor is 0.92 to 1.00, but in bilateral cases, it is 0.60 to 1.00.
-
Ninety percent of Wilms tumors are diagnosed before six years of age with the median age of diagnosis being 3.5 years. Overall 5-year survival in the US is 92% but in poor parts of the world with fewer resources, the survival rate is only 78%.
Wilm’s Tumor (Nephroblastoma) Market
The Wilm’s Tumor market size is anticipated to increase during the study period owing to the rising incident population of Nephroblastoma patients in the 7MM. Extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies will also fuel the market growth.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Wilm’s Tumor market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Wilm’s Tumor market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Wilm’s Tumor (Nephroblastoma) Epidemiology
The epidemiology section covers insights about the historical and current Wilm’s Tumor patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Wilm’s Tumor (Nephroblastoma) Epidemiology Segmentation
-
Total Prevalent cases of Wilm’s Tumor
-
Age-specific cases of Wilm’s Tumor
-
Gender-Specific cases of Wilm’s Tumor
-
Stage-specific cases of Wilm’s Tumor
Wilm’s Tumor (Nephroblastoma) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Wilm’s Tumor market or expected to get launched in the market during the study period. The analysis covers Wilm’s Tumor market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Wilm’s Tumor Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:-https://www.delveinsight.com/sample-request/wilms-tumor-market
Wilm’s Tumor (Nephroblastoma) Therapeutics Analysis
Wilm’s Tumor (Nephroblastoma) Companies:
-
Roche
-
Exelixis Inc.
-
Agios Pharmaceutical
-
Seattle Children’s Hospital
And many more.
Wilm’s Tumor (Nephroblastoma) Therapies covered in the report includes:
-
Entrectinib
-
Carbozantinib
-
Ivosidenib
-
EGFR806 CAR T Cell
-
Doxorubicin
-
Dactinomycin
-
Vincristine
And many others.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/wilms-tumor-market
Table of Content
1. Key Insights
2. Executive Summary
3. Wilm’s Tumor Competitive Intelligence Analysis
4. Wilm’s Tumor Market Overview at a Glance
5. Wilm’s Tumor Disease Background and Overview
6. Wilm’s Tumor Patient Journey
7. Wilm’s Tumor Epidemiology and Patient Population
8. Wilm’s Tumor Treatment Algorithm, Current Treatment, and Medical Practices
9. Wilm’s Tumor Unmet Needs
10. Key Endpoints of Wilm’s Tumor Treatment
11. Wilm’s Tumor Marketed Products
12. Wilm’s Tumor Emerging Therapies
13. Wilm’s Tumor Seven Major Market Analysis
14. Attribute Analysis
15. Wilm’s Tumor Market Outlook (7 major markets)
16. Wilm’s Tumor Access and Reimbursement Overview
17. KOL Views on the Wilm’s Tumor Market.
18. Wilm’s Tumor Market Drivers
19. Wilm’s Tumor Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/wilms-tumor-market
Other Latest Healthcare Reports By DelveInsight
Epstein Barr virus (EBV) Market
DelveInsight’s “Epstein Barr virus (EBV) Market” report delivers an in-depth understanding of the Epstein Barr virus (EBV), historical and forecasted epidemiology as well as the Epstein Barr virus (EBV) market trends in 7MM. As per DelveInsight, the Epstein Barr virus (EBV) Market is expected to grow in the coming years owing to the active participation of key companies such as Atara Biotherapeutics, AlloVir, Tessa Therapeutics, Viracta Therapeutics, Seagen, RAPT Therapeutics, Merck, Eutilex, Atara Biotherapeutics, Labolife, and Others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/